Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hormones
Published in: Hormones 2/2018

01-06-2018 | Review Article

Ischemic stroke and select adipose-derived and sex hormones: a review

Author: Kristy L. Meadows

Published in: Hormones | Issue 2/2018

Login to get access

Abstract

Ischemic stroke is the fifth leading cause of death in the USA and is the leading cause of serious, long-term disability worldwide. The principle sex hormones (estrogen, progesterone, and testosterone), both endogenous and exogenous, have profound effects on various stroke outcomes and have become the focus of a number of studies evaluating risk factors and treatment options for ischemic stroke. In addition, the expression of other hormones that may influence stroke outcome, including select adipose-derived hormones (adiponectin, leptin, and ghrelin), can be regulated by sex hormones and are also the focus of several ischemic stroke studies. This review aims to summarize some of the preclinical and clinical studies investigating the principle sex hormones, as well as select adipose-derived hormones, as risk factors or potential treatments for ischemic stroke. In addition, the potential for relaxin, a lesser studied sex hormone, as a novel treatment option for ischemic stroke is explored.
Literature
1.
Donnan GA, Fisher M, Macleod M, Davis SM (2008) Stroke. Lancet Lond. Engl 371:1612–1623CrossRef
2.
3.
Broussalis E et al (2012) Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. Drug Discov. Today 17:296–309PubMedCrossRef
4.
Neuhaus AA et al (2014) Importance of preclinical research in the development of neuroprotective strategies for ischemic stroke. JAMA Neurol 71:634–639PubMedCrossRef
5.
Fluri F, Schuhmann MK, Kleinschnitz C (2015) Animal models of ischemic stroke and their application in clinical research. Drug Des Devel Ther 9:3445–3454PubMedPubMedCentral
6.
Mozaffarian D et al (2016) Heart disease and stroke atatistics-2016 update: a report from the American Heart Association. Circulation 133:e38–e360PubMed
7.
Durukan A, Tatlisumak T (2007) Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 87:179–197PubMedCrossRef
8.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med 333:1581–1587CrossRef
9.
10.
Glendenning ML, Lovekamp-Swan T, Schreihofer DA (2008) Protective effect of estrogen in endothelin-induced middle cerebral artery occlusion in female rats. Neurosci Lett 445:188–192PubMedPubMedCentralCrossRef
11.
Herson PS, Palmateer J, Hurn PD (2013) Biological sex and mechanisms of ischemic brain injury. Transl Stroke Res 4:413–419PubMedCrossRef
12.
Hurn PD, Macrae IM (2000) Estrogen as a neuroprotectant in stroke. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 20:631–652CrossRef
13.
Koellhoffer EC, McCullough LD (2013) The effects of estrogen in ischemic stroke. Transl Stroke Res 4:390–401PubMedCrossRef
14.
Siegel C, Turtzo C, McCullough LD (2010) Sex differences in cerebral ischemia: possible molecular mechanisms. J Neurosci Res 88:2765–2774PubMedCrossRef
15.
16.
Zuo W, Zhang W, Chen N-H (2013) Sexual dimorphism in cerebral ischemia injury. Eur J Pharmacol 711:73–79PubMedCrossRef
17.
Caminos JE et al (2003) Expression of ghrelin in the cyclic and pregnant rat ovary. Endocrinology 144:1594–1602PubMedCrossRef
18.
Du C et al (2009) Expression of the orexigenic peptide ghrelin in the sheep ovary. Domest Anim Endocrinol 36:89–98PubMedCrossRef
19.
Tvarijonaviciute A, Carrillo-Sanchez JD, Ceron JJ (2013) Effect of estradiol and progesterone on metabolic biomarkers in healthy bitches. Reprod Domest Anim Zuchthyg 48:520–524CrossRef
20.
DeLahunta, A., Glass, E. & Kent, M. Veterinary neuroanatomy and clinical neurology. (Elsevier, 2015)
21.
Garosi L, Cerebrovascular S (2010) Disease in dogs and cats. Vet Clin North Am Small Anim Pract 40:65–79PubMedCrossRef
22.
Henderson VW, Lobo RA (2012) Hormone therapy and the risk of stroke: perspectives 10 years after the Women’s Health Initiative trials. Climacteric J Int Menopause Soc 15:229–234CrossRef
23.
24.
Balaskó M, Soós S, Székely M, Pétervári E (2014) Leptin and aging: review and questions with particular emphasis on its role in the central regulation of energy balance. J Chem Neuroanat 61–62:248–255PubMedCrossRef
25.
Pétervári E et al (2014) Age versus nutritional state in the development of central leptin resistance. Peptides 56:59–67PubMedCrossRef
26.
Ebrahimi-Mamaeghani M, Mohammadi S, Arefhosseini SR, Fallah P, Bazi Z (2015) Adiponectin as a potential biomarker of vascular disease. Vasc Health Risk Manag 11:55–70PubMedPubMedCentral
27.
Kantorová E et al (2015) The intricate network of adipokines and stroke. Int J Endocrinol 2015(967698)
28.
Matsumoto M, Ishikawa S, Kajii E (2008) Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke J. Cereb. Circ. 39:323–328CrossRef
29.
Meier U (2004) Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50:1511–1525PubMedCrossRef
30.
Vaiopoulos AG, Marinou K, Christodoulides C, Koutsilieris M (2012) The role of adiponectin in human vascular physiology. Int J Cardiol 155:188–193PubMedCrossRef
31.
32.
Schäfer K, Konstantinides S (2011) Adipokines and thrombosis. Clin Exp Pharmacol Physiol 38:864–871PubMedCrossRef
33.
Song J, Lee WT, Park KA, Lee JE (2014) Association between risk factors for vascular dementia and adiponectin. Biomed Res Int 2014:261672PubMedPubMedCentral
34.
Chen M-P et al (2005) Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25:821–826PubMedCrossRef
35.
Kuwashiro T et al (2014) Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke—Research for Biomarkers in Ischemic Stroke (REBIOS). Metabolism 63:1093–1103PubMedCrossRef
36.
Söderberg S et al (2004) Leptin, but not adiponectin, predicts stroke in males. J Intern Med 256:128–136PubMedCrossRef
37.
Wolf I et al (2006) Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 106:966–973PubMedCrossRef
38.
Arregui M et al (2014) Adiponectin and risk of stroke: prospective study and meta-analysis. Stroke J. Cereb. Circ. 45:10–17CrossRef
39.
Bienek R et al (2012) Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke. Endokrynol Pol 63:338–345PubMed
40.
Gardener H et al (2013) Adiponectin and risk of vascular events in the Northern Manhattan study. Atherosclerosis 226:483–489PubMedCrossRef
41.
Kos K et al (2007) Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab 92:1129–1136PubMedCrossRef
42.
Bidulescu A et al (2013) Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in African Americans: the Jackson heart study. Front Public Health 1:16PubMedPubMedCentralCrossRef
43.
Kizer JR et al (2013) Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J Clin Endocrinol Metab 98:255–263PubMedCrossRef
44.
45.
Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021–45026PubMedCrossRef
46.
Tomicek NJ, Hunter JC, Machikas AM, Lopez V, Korzick DH (2015) Acute adiponectin delivery is cardioprotective in the aged female rat heart. Geriatr Gerontol Int 15:636–646PubMedCrossRef
47.
Yatomi K et al (2009) Pathophysiological dual action of adiponectin after transient focal ischemia in mouse brain. Brain Res 1297:169–176PubMedCrossRef
48.
Chen B et al (2009) Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Res 1273:129–137PubMedCrossRef
49.
50.
Nishimura M et al (2008) Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117:216–223PubMedCrossRef
51.
Song W et al (2015) Therapeutic window of globular adiponectin against cerebral ischemia in diabetic mice: the role of dynamic alteration of adiponectin/adiponectin receptor expression. Sci Rep 5:17310PubMedPubMedCentralCrossRef
52.
Shen L-H, Miao J, Zhao Y-J, Zhao Y-J, Liang W (2014) Expression of brain adiponectin in a murine model of transient cerebral ischemia. Int J Clin Exp Med 7:4590–4596PubMedPubMedCentral
53.
54.
Kishida K, Funahashi T, Shimomura I (2014) Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 28:119–130PubMedCrossRef
55.
McEntegart MB et al (2007) Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 28:829–835PubMedCrossRef
56.
Kantorova E et al (2011) Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke. Neuro Endocrinol Lett 32:716–721PubMed
57.
Kim BJ, Lee S-H, Ryu W-S, Kim CK, Yoon B-W (2012) Adipocytokines and ischemic stroke: differential associations between stroke subtypes. J Neurol Sci 312:117–122PubMedCrossRef
58.
Efstathiou SP et al (2005) Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke J. Cereb. Circ. 36:1915–1919CrossRef
59.
Nagasawa H, Yokota C, Toyoda K, Ito A, Minematsu K (2011) High level of plasma adiponectin in acute stroke patients is associated with stroke mortality. J Neurol Sci 304:102–106PubMedCrossRef
60.
Stott DJ et al (2009) Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol 38:253–261PubMedCrossRef
61.
Gardener H et al (2012) Adiponectin and carotid intima-media thickness in the northern Manhattan study. Stroke J. Cereb. Circ. 43:1123–1125CrossRef
62.
Prugger C et al (2012) Adipocytokines and the risk of ischemic stroke: the PRIME study. Ann Neurol 71:478–486PubMedCrossRef
63.
Rajpathak SN et al (2011) Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women’s Health Initiative. Stroke J. Cereb. Circ. 42:1813–1820CrossRef
64.
Ogorodnikova AD et al (2010) High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women’s Health Initiative Study. Stroke J. Cereb. Circ. 41:1376–1381CrossRef
65.
Kanhai DA et al (2013) Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev Off J Int Assoc Study Obes 14:555–567CrossRef
66.
Park H-K, Ahima RS (2015) Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism 64:24–34PubMedCrossRef
67.
68.
Wilkinson M, Brown R, Imran SA, Ur E (2007) Adipokine gene expression in brain and pituitary gland. Neuroendocrinology 86:191–209PubMedCrossRef
69.
Paz-Filho GJ (2016) The effects of leptin replacement on neural plasticity. Neural Plast 2016(8528934)
70.
71.
Denis RGP, Bing C, Naderali EK, Vernon RG, Williams G (2003) Lactation modulates diurnal expression profiles of specific leptin receptor isoforms in the rat hypothalamus. J Endocrinol 178:225–232PubMedCrossRef
72.
Khafaji HARH, Bener AB, Rizk NM, Al Suwaidi J (2012) Elevated serum leptin levels in patients with acute myocardial infarction; correlation with coronary angiographic and echocardiographic findings. BMC Res Notes 5:262PubMedPubMedCentralCrossRef
73.
Mu J, Ostrowski RP, Krafft PR, Tang J, Zhang JH (2013) Serum leptin levels decrease after permanent MCAo in the rat and remain unaffected by delayed hyperbaric oxygen therapy. Med Gas Res 3:8PubMedPubMedCentralCrossRef
74.
75.
Liu J et al (2010) Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin Endocrinol 72(32–37)
76.
Lukasik M et al (2012) Reactive leptin resistance and the profile of platelet activation in acute ischaemic stroke patients. Thromb Haemost 108:107–118PubMedCrossRef
77.
Sierra-Johnson J et al (2007) Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol 100:234–239PubMedPubMedCentralCrossRef
78.
Söderberg S et al (2003) High leptin levels are associated with stroke. Cerebrovasc Dis Basel Switz 15:63–69CrossRef
79.
Signore AP, Zhang F, Weng Z, Gao Y, Chen J (2008) Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. J Neurochem 106:1977–1990PubMedPubMedCentralCrossRef
80.
Zhang F, Wang S, Signore AP, Chen J (2007) Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke J Cereb Circ 38:2329–2336CrossRef
81.
Valerio A et al (2009) Leptin is induced in the ischemic cerebral cortex and exerts neuroprotection through NF-kappaB/c-Rel-dependent transcription. Stroke J. Cereb. Circ. 40:610–617CrossRef
82.
Zhang J et al (2013) Leptin attenuates cerebral ischemia injury through the promotion of energy metabolism via the PI3K/Akt pathway. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 33:567–574CrossRef
83.
Zhang J et al (2011) Leptin attenuates cerebral ischemia/reperfusion injury partially by CGRP expression. Eur J Pharmacol 671:61–69PubMedCrossRef
84.
Avraham Y et al (2013) Delayed leptin administration after stroke induces neurogenesis and angiogenesis. J Neurosci Res 91:187–195PubMedCrossRef
85.
Deng Z-H et al (2014) Inhibition of the connexin 43 elevation may be involved in the neuroprotective activity of leptin against brain ischemic injury. Cell Mol Neurobiol 34:871–879PubMedCrossRef
86.
Calleja AI et al (2013) Blood biomarkers of insulin resistance in acute stroke patients treated with intravenous thrombolysis: temporal profile and prognostic value. J Diabetes Res Clin Metab 2:2CrossRef
87.
Jalil A, Amir S, Majeed R, Jalil F (2010) Circulating leptin levels in elderly subjects with and without cerebrovasular disease. J Coll Physicians Surg—Pak JCPSP 20:350–351PubMed
88.
89.
Jiménez I et al (2009) High serum levels of leptin are associated with post-stroke depression. Psychol Med 39:1201–1209PubMedCrossRef
90.
Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N (2013) Adiposity, adipokines, and risk of incident stroke in older men. Stroke J. Cereb. Circ. 44:3–8CrossRef
91.
Zeng R, Xu C-H, Xu Y-N, Wang Y-L, Wang M (2014) Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis. Arq Bras Endocrinol Metabol 58:817–823PubMedCrossRef
92.
Ciccone M et al (2001) Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord J Int Assoc Study Obes 25:805–810CrossRef
93.
Norata GD et al (2007) Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke J. Cereb. Circ. 38:2844–2846CrossRef
94.
95.
Saber H et al (2015) Serum leptin levels and the risk of stroke: the Framingham study. Stroke J. Cereb. Circ. 46:2881–2885CrossRef
96.
Andrews ZB (2011) Central mechanisms involved in the orexigenic actions of ghrelin. Peptides 32:2248–2255PubMedCrossRef
97.
Andrews ZB (2011) The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci 34:31–40PubMedCrossRef
98.
Solomou S, Korbonits M (2014) The role of ghrelin in weight-regulation disorders: implications in clinical practice. Horm Athens Greece 13:458–475
99.
Jeusette IC et al (2005) Effects of chronic obesity and weight loss on plasma ghrelin and leptin concentrations in dogs. Res Vet Sci 79:169–175PubMedCrossRef
100.
Stoyanova II (2014) Ghrelin: a link between ageing, metabolism and neurodegenerative disorders. Neurobiol. Dis 72 Pt A:72–83PubMedCrossRef
101.
102.
Garcia JM et al (2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 16:108–116PubMedCrossRef
103.
Seyhanli ES et al (2015) Assessment of serum and urine ghrelin levels in patients with acute stroke. Int J Clin Exp Med 8:722–729PubMedPubMedCentral
104.
Dos Santos VV et al (2013) Ghrelin as a neuroprotective and palliative agent in Alzheimer’s and Parkinson’s disease. Curr Pharm Des 19:6773–6790PubMedCrossRef
105.
Wu R et al (2005) Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res 68:318–326PubMedCrossRef
106.
Moon M et al (2011) Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-β1-42 oligomer-injected mice. J Alzheimers Dis JAD 23:147–159PubMedCrossRef
107.
Xu X, Zhu Y, Chuai J (2012) Changes in serum ghrelin and small intestinal motility in rats with ischemic stroke. Anat Rec Hoboken NJ 2007(295):307–312CrossRef
108.
Cheyuo C et al (2011) Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. Shock Augusta Ga 35:258–265CrossRef
109.
Kenny R et al (2013) Endogenous ghrelin’s role in hippocampal neuroprotection after global cerebral ischemia: does endogenous ghrelin protect against global stroke? Am J Physiol Regul Integr Comp Physiol 304:R980–R990PubMedCrossRef
110.
Matsumoto M et al (2013) Decreased serum ghrelin levels in patients with acute myocardial infarction. Tohoku J Exp Med 231:235–242PubMedCrossRef
111.
Sax B et al (2013) Characterization of pericardial and plasma ghrelin levels in patients with ischemic and non-ischemic heart disease. Regul Pept 186:131–136PubMedCrossRef
112.
Kadoglou NPE et al (2014) Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis. Peptides 57:12–16PubMedCrossRef
113.
Xu X-D, Shao F (2015) Enteral ecoimmunonutrition reduced enteral permeability and serum ghrelin activity in severe cerebral stroke patients with lung infection. Cell Biochem Biophys 71:195–198PubMedCrossRef
114.
Ritzel RM, Capozzi LA, McCullough LD (2013) Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke. Horm Behav 63:238–253PubMedCrossRef
115.
Duckles SP, Krause DN (2007) Cerebrovascular effects of oestrogen: multiplicity of action. Clin Exp Pharmacol Physiol 34:801–808PubMedCrossRef
116.
117.
Schreihofer DA, Ma Y (2013) Estrogen receptors and ischemic neuroprotection: who, what, where, and when? Brain Res 1514:107–122PubMedCrossRef
118.
119.
Scott E, Zhang Q, Wang R, Vadlamudi R, Brann D (2012) Estrogen neuroprotection and the critical period hypothesis. Front Neuroendocrinol 33:85–104PubMedCrossRef
120.
Bramlett HM (2005) Sex differences and the effect of hormonal therapy on ischemic brain injury. Pathophysiology 12:17–27PubMedCrossRef
121.
122.
Geary GG, Krause DN, Duckles SP (1998) Estrogen reduces myogenic tone through a nitric oxide-dependent mechanism in rat cerebral arteries. Am J Phys 275:H292–H300
123.
124.
125.
Manwani B et al (2013) Differential effects of aging and sex on stroke induced inflammation across the lifespan. Exp Neurol 249:120–131PubMedCrossRef
126.
Gibson CL, Gray LJ, Murphy SP, Bath PMW (2006) Estrogens and experimental ischemic stroke: a systematic review. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 26:1103–1113CrossRef
127.
Liu F, Yuan R, Benashski SE, McCullough LD (2009) Changes in experimental stroke outcome across the life span. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 29:792–802CrossRef
128.
Liu F, Benashski SE, Xu Y, Siegel M, McCullough LD (2012) Effects of chronic and acute oestrogen replacement therapy in aged animals after experimental stroke. J Neuroendocrinol 24:319–330PubMedPubMedCentralCrossRef
129.
Viscoli CM et al (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249PubMedCrossRef
130.
Wassertheil-Smoller S et al (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 289:2673–2684PubMedCrossRef
131.
132.
Maggio M et al (2009) Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. J Am Geriatr Soc 57:1810–1815PubMedPubMedCentralCrossRef
133.
134.
Pappa T et al (2012) Estradiol levels predict short-term adverse health outcomes in postmenopausal acute stroke women. Eur J Neurol 19:1300–1304PubMedCrossRef
135.
Schumacher M et al (2014) Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog Neurobiol 113:6–39PubMedCrossRef
136.
Gibson CL, Coomber B, Rathbone J (2009) Is progesterone a candidate neuroprotective factor for treatment following ischemic stroke? Neurosci Rev J Bringing Neurobiol Neurol Psychiatry 15:324–332
137.
Gibson CL, Gray LJ, Bath PMW, Murphy SP (2008) Progesterone for the treatment of experimental brain injury; a systematic review. Brain J Neurol 131:318–328CrossRef
138.
Wong R et al (2013) Progesterone treatment for experimental stroke: an individual animal meta-analysis. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 33:1362–1372CrossRef
139.
Peterson BL, Won S, Geddes RI, Sayeed I, Stein DG (2015) Sex-related differences in effects of progesterone following neonatal hypoxic brain injury. Behav Brain Res 286:152–165PubMedCrossRef
140.
141.
142.
Quillinan N, Deng G, Grewal H, Herson PS (2014) Androgens and stroke: good, bad or indifferent? Exp Neurol 259:10–15PubMedCrossRef
143.
Geary GG, Krause DN, Duckles SP (2000) Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. Am J Physiol Heart Circ Physiol 279:H610–H618PubMedCrossRef
144.
Gonzales RJ, Krause DN, Duckles SP (2004) Testosterone suppresses endothelium-dependent dilation of rat middle cerebral arteries. Am J Physiol Heart Circ Physiol 286:H552–H560PubMedCrossRef
145.
146.
Gibson CL (2013) Cerebral ischemic stroke: is sex important? J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 33:1355–1361CrossRef
147.
148.
Olsen TS, Andersen KK (2010) Female survival advantage relates to male inferiority rather than female superiority: a hypothesis based on the impact of age and stroke severity on 1-week to 1-year case fatality in 40,155 men and women. Gend Med 7:284–295PubMedCrossRef
149.
150.
151.
Halls ML, Bathgate RAD, Sutton SW, Dschietzig TB, Summers RJ (2015) International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1–4, the receptors for relaxin family peptides. Pharmacol. Rev 67:389–440PubMedPubMedCentralCrossRef
152.
153.
Dschietzig T, Bartsch C, Baumann G, Stangl K (2006) Relaxin—a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 112:38–56PubMedCrossRef
154.
Jelinic M et al (2014) Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J Off Publ Fed Am Soc Exp Biol 28:275–287
155.
Xu Q, Chakravorty A, Bathgate RAD, Dart AM, Du XJ (2010) Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension 55:1260–1266PubMedCrossRef
156.
Dschietzig T, Bartsch C, Baumann G, Stangl K (2009) RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin–GR pathway. Regul Pept 154:77–84PubMedCrossRef
157.
158.
Yoshida T, Kumagai H, Kohsaka T, Ikegaya N (2013) Relaxin protects against renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 305:F1169–F1176PubMedCrossRef
159.
Alexiou K, Wilbring M, Matschke K, Dschietzig T (2013) Relaxin protects rat lungs from ischemia-reperfusion injury via inducible NO synthase: role of ERK-1/2, PI3K, and forkhead transcription factor FKHRL1. PLoS One 8:e75592PubMedPubMedCentralCrossRef
160.
Brecht A, Bartsch C, Baumann G, Stangl K, Dschietzig T (2011) Relaxin inhibits early steps in vascular inflammation. Regul Pept 166:76–82PubMedCrossRef
161.
Teerlink JR et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39PubMedCrossRef
162.
Schöndorf T et al (2007) Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus. Clin Lab 53:193–198PubMed
163.
Schöndorf T et al (2007) Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 23:356–360CrossRef
164.
Leo CH, Jelinic M, Parkington HC, Tare M, Parry LJ (2014) Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. J Am Heart Assoc 3:e000493PubMedPubMedCentralCrossRef
165.
Dschietzig T et al (2003) Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 92:32–40PubMedCrossRef
166.
Chan S-L, Cipolla MJ (2011) Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor. FASEB J 25:3229–3239PubMedPubMedCentralCrossRef
167.
Chan S-L, Sweet JG, Cipolla MJ (2013) Treatment for cerebral small vessel disease: effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 27:3917–3927
168.
169.
Wilson BC, Rappaport R (2009) An in vitro study of the protective effect of relaxin on brain tissue under ischemic stress. Ann N Y Acad Sci 1160:265–268PubMedCrossRef
170.
Wilson BC (2005) Relaxin pretreatment decreases infarct size in male rats after middle cerebral artery occlusion. Ann N Y Acad Sci 1041:223–228PubMedCrossRef
171.
Wilson BC, Connell B, Saleh TM (2006) Relaxin-induced reduction of infarct size in male rats receiving MCAO is dependent on nitric oxide synthesis and not estrogenic mechanisms. Neurosci Lett 393:160–164PubMedCrossRef
172.
Bergeron LH et al (2015) Relaxin peptide hormones are protective during the early stages of ischemic stroke in male rats. Endocrinology 156:638–646PubMedCrossRef
173.
Milia P et al (2013) Efficacy of relaxin on functional recovery of post stroke patients. Ital J Anat Embryol Arch Ital Anat Ed Embriologia 118:92–97
174.
Savopoulos C, Michalakis K, Apostolopoulou M, Miras A, Hatzitolios A (2011) Adipokines and stroke: a review of the literature. Maturitas 70:322–327PubMedCrossRef
175.
Binder C et al (2014) Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain. Clin Exp Metastasis 31:57–65PubMedCrossRef
176.
Lamp O et al (2013) The metastatic potential of canine mammary tumours can be assessed by mRNA expression analysis of connective tissue modulators. Vet Comp Oncol 11:70–85PubMedCrossRef
Metadata
Title
Ischemic stroke and select adipose-derived and sex hormones: a review
Author
Kristy L. Meadows
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Hormones / Issue 2/2018
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI
https://doi.org/10.1007/s42000-018-0034-4

Other articles of this Issue 2/2018

Hormones 2/2018 Go to the issue

Original Article

Clinical and epidemiological characteristics of pituitary tumours in a single centre in Saudi Arabia

Historical Note

The thyroid gland in ancient Greece: a historical perspective

Historical Note

The thymus gland in ancient Greek medicine

Original Article

The low levels of bone morphogenic protein-4 and its antagonist noggin in type 2 diabetes

Review

The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis

Review Article

The development of probiotics therapy to obesity: a therapy that has gained considerable momentum
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits